GlobalData on MSN

AbbVie reports topline data from Phase I ABBV-295 trial

The MAD portion of the study enrolled a total of 76 participants.

CytomX outlines registrational trial plans for Varseta-M in third-line colorectal cancer with initial study start in 2027

Q4 2025 Management View CEO Sean McCarthy highlighted an update on Phase I dose expansion data for Varseta-M, the company's EpCAM-targeting PROBODY antibody drug conjugate for colorectal cancer, ...
ascopubs.org

Phase I Study of Subcutaneous Rituximab Hyaluronidase Combined With CHOP Chemotherapy for the Treatment of Diffuse Large B-Cell Lymphoma in Uganda

This open-label phase I study enrolled patients 18 years or older with newly diagnosed DLBCL. The first cohort (n = 6) received intravenous rituximab plus CHOP. This cohort received sqR for subsequent ...
ascopubs.org

ONITT: A phase I study of nanoliposomal irinotecan with talazoparib or temozolomide in children and young adults with recurrent or refractory solid tumors.

Phase II assessment of carboplatin with etoposide and high-dose ifosfamide in rEECur, an international randomised controlled trial of chemotherapy for the treatment of recurrent and primary refractory ...
Zacks Investment Research on MSN

JNJ's bladder cancer therapy meets key goal in early-stage study

Johnson & Johnson JNJ reported positive results from an early-stage study evaluating its investigational intravesical drug-releasing system with erdafitinib (Erda-iDRS) in patients with ...
Nasdaq

Immutep Announces Positive Update from Phase I Study of IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases

Initial pharmacological data from placebo-controlled, double-blind Phase I study shows significant T cell suppression and a favourable safety profile at dosing level of 0.9 mg/kg The substantial ...